Study Group: Physicians who Treat Peripheral Vascular Disease
Council Members in this Study Group: 265
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Charles O'Shaughnessy
Director of Interventional Cardiology
NORTH OHIO HEART CENTER, INC
Charles O'Shaughnessy, MD, is the Director of Interventional Cardiology at North Ohio Heart Center, Ohio. Dr. O'Shaughnessy's clinical interests are in interventional cardiology including balloon angioplasty, laser directional atherectomy, stent placement,...
Rohit AroraProfessor of Medicine
Finch University of Health Science-Chicago Medical SchoolRohit Arora, MD, FACC, FAHA, FASCI, FACP, is Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Previously,...
John HewettPartner
Pacific InterventionalJ. Joseph Hewett, MD is the Medical Director of Vascular Access Centers of South Los Angeles, Vascular Access Center of Los Angeles, and Newport Cancer Care Diagnostic Imaging and Interventions. He is a managing partner in Pacific Interventional which...
- Dan Streja
Clinical Professor of Medicine
UNIVERSITY OF CALIFORNIA, LOS ANGELESDan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA...
- Jack Rubin
Medical Director and Chief Executive Officer
Los Angeles Vascular Access CenterJack Rubin, MD, is the Medical Director of Davita Los Angeles Dialysis Center in California, since January 1999. Dr. Rubin is also the Medical Director and Chief Executive Officer of Los Angeles Vascular Access Center (LAVAC) in Inglewood, California,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
August 21, 2008
Analysis by: Marc Hamet, Clinical Professor,Heart Stents No Better Than Drugs for Chest Pain Over Time | www.bloomberg.com
This article could easily be spun as a victory for stent efficacy.
-
Tekturan losers blood pressure and proteinuria simultaneously
May 27, 2008
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these is proteinuria.
-
Preventing Bariatric Surgery Deaths
January 25, 2008
Pinning Down Mortality Rates After Bariatric Surgery | www.medscape.com
Bariatric surgery is a major operative procedure that caries significant morbidity and mortality risks due to the comorbid diseases seen in this patient population. This procedure is increasing in frequency as more patients are willing to have it and more surgeons are becoming proficient. The mortality rate is ~ 1 % at 1 year and 6% at 5 years which is greater than the population at large.
-
Outsourcing of compassionate use of drugs?
January 18, 2008
Analysis by: Dan Streja, Clinical Professor of Medicine,No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.
-
November 23, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Partner